These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25560463)

  • 1. Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.
    Geipel A; Seiz PL; Niekamp H; Neumann-Fraune M; Zhang K; Kaiser R; Protzer U; Gerlich WH; Glebe D;
    Antivir Ther; 2015; 20(8):779-87. PubMed ID: 25560463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
    Tenney DJ; Rose RE; Baldick CJ; Levine SM; Pokornowski KA; Walsh AW; Fang J; Yu CF; Zhang S; Mazzucco CE; Eggers B; Hsu M; Plym MJ; Poundstone P; Yang J; Colonno RJ
    Antimicrob Agents Chemother; 2007 Mar; 51(3):902-11. PubMed ID: 17178796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
    Tenney DJ; Levine SM; Rose RE; Walsh AW; Weinheimer SP; Discotto L; Plym M; Pokornowski K; Yu CF; Angus P; Ayres A; Bartholomeusz A; Sievert W; Thompson G; Warner N; Locarnini S; Colonno RJ
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3498-507. PubMed ID: 15328117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
    Villet S; Ollivet A; Pichoud C; Barraud L; Villeneuve JP; Trépo C; Zoulim F
    J Hepatol; 2007 Mar; 46(3):531-8. PubMed ID: 17239478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.
    Karatayli E; Karatayli SC; Cinar K; Gokahmetoglu S; Güven K; Idilman R; Yurdaydin C; Bozdayi AM
    J Clin Virol; 2012 Feb; 53(2):130-4. PubMed ID: 22078148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of HBV rtH55R polymerase substitution on viral replication and rtM204I/V resistance to nucleoside/nucleotide antiviral drugs.
    Xiang KH; Zhao CY; Wang S; Li Y; Su MZ; Wang QY; Xu XZ; Deng J; Zhuang H; Li T
    Antivir Ther; 2018; 23(1):33-42. PubMed ID: 28440785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.
    Baldick CJ; Eggers BJ; Fang J; Levine SM; Pokornowski KA; Rose RE; Yu CF; Tenney DJ; Colonno RJ
    J Hepatol; 2008 Jun; 48(6):895-902. PubMed ID: 18362040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.
    Lee JH; Hong SP; Jang ES; Park SJ; Hwang SG; Kang SK; Jeong SH
    J Med Virol; 2015 Jun; 87(6):993-8. PubMed ID: 25712861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus.
    Zhang Y; Zhang Y; Kang Y; Wang J; Liu H; Zhu H; Qin Y; Mao R; Lin X; Lu M; Zhang J
    J Virol Methods; 2014 Jun; 201():51-6. PubMed ID: 24583110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?
    Lee GH; Aung MO; Dan YY; Lee YM; Mak B; Low HC; Lim K; Thwin MA; Tan PS; Lim SG
    J Med Virol; 2013 Jan; 85(1):26-33. PubMed ID: 23023992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
    Rodriguez-Frias F; Jardi R; Schaper M; Gimferrer M; Elefsiniotis I; Tabernero D; Esteban R; Buti M
    J Med Virol; 2007 Nov; 79(11):1671-3. PubMed ID: 17854030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
    Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
    Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.
    Zhang Y; He S; Li QL; Guo JJ
    Virus Res; 2013 Nov; 177(2):156-62. PubMed ID: 23968804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation.
    Luo YY; Tao Y; Cai XF; Zhang WL; Long QX; Guo H; Huang AL; Hu JL
    Antiviral Res; 2016 Feb; 126():99-107. PubMed ID: 26738784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
    Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
    AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.